In 2011 was created iGan Partners, which is appeared as VC. The venture was found in North America in Canada. The leading representative office of defined VC is situated in the Toronto.
This organization was formed by Sam Ifergan. We also calculated 4 valuable employees in our database.
The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the iGan Partners, startups are often financed by MaRS Investment Accelerator Fund, Right Side Capital Management, LVL1 Group. The meaningful sponsors for the fund in investment in the same round are Rho Canada Ventures, Motorola Solutions Venture Capital, MaRS Investment Accelerator Fund. In the next rounds fund is usually obtained by LVL1 Group, Lumira Ventures, Upfront Ventures.
The average startup value when the investment from iGan Partners is 1-5 millions dollars. Deals in the range of 1 - 5 millions dollars are the general things for fund. The real fund results show that this VC is 22 percentage points more often commits exit comparing to other companies. This iGan Partners works on 12 percentage points less the average amount of lead investments comparing to the other organizations. The increased amount of exits for fund were in 2018. The fund is generally included in 2-6 deals every year. The high activity for fund was in 2017. Despite it in 2019 the fund had an activity.
The fund has no exact preference in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Canada. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular fund investment industries, there are FinTech, Health Care. Among the most popular portfolio startups of the fund, we may highlight Think Research, Flosonics, Rna Diagnostics.
Funds with similar focus
|Adverline||France, Ile-de-France, Paris|
|Allianz Private Equity Partners||New York, New York, United States|
|Asia Pacific Ventures||California, Redwood City, United States|
|Asian E-Commerce Alliance||Germany, Hamburg|
|Bridger Management||Lee, Massachusetts, United States|
|Foreign & Commonwealth Office - UK||England, London, United Kingdom|
|GOVTOR||China, Jiangsu, Nanjing|
|Grand Flight Investment||China, Shanghai|
|Harbourton||New Jersey, Princeton, United States|
|Hiro Capital||Luxembourg, Luxembourg|
|LVP Life Science Ventures||-|
|Nestor||France, Ile-de-France, Paris|
|Opportunity Capital Partners||Chicago, Illinois, United States|
|RBC Capital||Canada, Ontario, Toronto|
|U.S. Bancorp||Minneapolis, Minnesota, United States|
|Value4Capital||Mazowieckie, Poland, Warsaw|
|ZenStone Venture Capital||California, Santa Clara, United States|
|11 Aug 2022||Old Toronto, Ontario, Canada|
|$3M||04 Apr 2022||Old Toronto, Ontario, Canada|
|$4M||01 Mar 2022||Old Toronto, Ontario, Canada|
Hyivy Health Inc.
|$874K||18 Jan 2022||Hamilton, Ontario, Canada|
Hyivy Health Inc.
|$874K||01 May 2021||Hamilton, Ontario, Canada|
|$17M||22 Apr 2021||Toronto, Ontario, Canada|
|$14M||02 Feb 2021||Greater Sudbury, Ontario, Canada|
|29 Nov 2019||Canada, Ontario|
|$250K||01 Nov 2019||Canada, Ontario|
– Medchart announced that it has raised $17M in Seed and Series A funding led by Crosslink Capital and Golden Ventures, with additional funds from Vast Ventures, Union Ventures, iGan Partners, Stanford Law School, and Nas, an original backer.
– The company will apply the current investment to accelerate product innovation and hire new talent to meet the widespread demand for businesses to get patient-authorized health information.
– Medchart squarely addresses one of the slowest, most tedious, and fractured processes: getting patient health records for common business tasks.
– Medchart lets businesses easily, securely, and cost-effectively access and exchange patient-authorized digital health information for everything from life sciences real-world evidence or insurance underwriting to legal claims.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.